Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.

NCT Number	NCT07059611
Lead Sponsor	Abramson Cancer Center at Penn Medicine Collaborators: Replimune, Inc.
Conditions	Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment	34 participants
Start Date	2026-09-01
Primary Completion	2027-11-01 (estimated)
Study Completion	2029-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-05